MedPath
Found 53 clinical trials|View Analysis
Sort by:

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

Phase 4
Recruiting
Conditions
HIV-1-infection
Interventions
Drug: E/C/F/TAF
Drug: F/TAF (High Dose Tablet)
Drug: B/F/TAF (Low Dose)
Drug: E/C/F/TAF (Low Dose)
Drug: F/TAF (Low Dose Tablet)
Drug: F/TAF (Lowest Dose Tablet)
Drug: F/TAF (High Dose TOS)
Drug: B/F/TAF (High Dose)
Drug: F/TAF (Low Dose TOS)
Drug: B/F/TAF (Lowest Dose TOS)
Drug: F/TAF (Lowest Dose TOS)
Drug: B/F/TAF (High Dose TOS)
Drug: Cobicistat (High Dose)
Drug: 3rd ARV Agent
Drug: Cobicistat (Low Dose)
Drug: Cobicistat (TOS)
Drug: B/F/TAF (Low Dose TOS)
Drug: Nucleos(t)ide reverse transcriptase inhibitors (NRTI)
Drug: ATV
Drug: DRV
Drug: Lopinavir Boosted with ritonavir (LPV/r)
First Posted Date
2024-03-29
Last Posted Date
2024-12-24
Lead Sponsor
Gilead Sciences
Target Recruit Count
350
Registration Number
NCT06337032
Locations
🇦🇷

Helios Salud, Buenos Aires, Argentina

🇵🇦

Hospital del Niño, Panama City, Panama

🇿🇦

Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa

and more 4 locations

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Recruiting
Conditions
Tuberculosis
HIV Infections
Interventions
Drug: Bictegravir (BIC)
Drug: Doravirine (DOR)
Drug: Tenofovir alafenamide (TAF)
Drug: Cabotegravir (CAB)
Drug: Atazanavir/ritonavir (ATV/r)
Drug: Lopinavir/ritonavir (LPV/r)
Drug: Second-Line TB Treatment
Drug: Dolutegravir (DTG)
Drug: Cobicistat
Drug: First-Line TB Treatment
Drug: Darunavir/ritonavir (DRV/r)
Drug: Ritonavir
First Posted Date
2020-08-19
Last Posted Date
2024-08-21
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
325
Registration Number
NCT04518228
Locations
🇺🇸

Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States

🇺🇸

Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States

🇿🇦

Wits RHI Shandukani Research, Johannesburg, Gauteng, South Africa

and more 34 locations

Mindfulness Intervention and Symptom Variability in Hearing

Not Applicable
Withdrawn
Conditions
Hearing Loss
Interventions
Behavioral: Attention to Variability (ATV)
Other: Placebo
First Posted Date
2020-02-24
Last Posted Date
2022-02-17
Lead Sponsor
Harvard University
Registration Number
NCT04281225
Locations
🇺🇸

Harvard University, Cambridge, Massachusetts, United States

Determine the Tolerability and Safety of Atovaquone-proguanil (ATV-PG) Co-administered With Amodiaquine (AQ)

Phase 1
Completed
Conditions
Malaria
Interventions
Drug: ATV-PG 1000-400 mg + AQ 612 mg
First Posted Date
2019-06-28
Last Posted Date
2020-03-19
Lead Sponsor
Medicines for Malaria Venture
Target Recruit Count
44
Registration Number
NCT04002687
Locations
🇬🇧

Richmond Pharmacology Ltd., Croydon, London, United Kingdom

Socket Augmentation Using Platelet Concentrates, Atorvastatin Gel or Combination

Phase 4
Completed
Conditions
Alveolar Socket Preservations
Interventions
Drug: ATV gel
Biological: PRF
Biological: PRGF
Combination Product: PRGF/ATV
First Posted Date
2017-07-27
Last Posted Date
2017-07-27
Lead Sponsor
Ain Shams University
Target Recruit Count
50
Registration Number
NCT03231137

Socket Augmentation Using Atorvastatin With Or Without PRGF (Clinical and Histomorphometric Study)

Phase 4
Completed
Conditions
Socket Preservation
Interventions
Drug: ATV gel
Drug: PRGF/ATV
First Posted Date
2017-07-25
Last Posted Date
2018-09-24
Lead Sponsor
Ain Shams University
Target Recruit Count
30
Registration Number
NCT03228771
Locations
🇪🇬

Faculty of dentistry-Ain shams University, Cairo, Egypt

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

Phase 3
Completed
Conditions
HIV-1 Infection
Interventions
Drug: B/F/TAF
Drug: E/C/F/TAF
Drug: E/C/F/TDF
Drug: ATV
Drug: RTV
Drug: FTC/TDF
First Posted Date
2016-01-12
Last Posted Date
2020-03-04
Lead Sponsor
Gilead Sciences
Target Recruit Count
472
Registration Number
NCT02652624

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

Phase 3
Completed
Conditions
HIV-1 Infection
Interventions
Drug: B/F/TAF
Drug: RTV
Drug: ATV
Drug: DRV
Drug: COBI
Drug: ATV/co
Drug: DRV/co
Drug: FTC/TDF
Drug: ABC/3TC
First Posted Date
2015-11-11
Last Posted Date
2020-12-29
Lead Sponsor
Gilead Sciences
Target Recruit Count
578
Registration Number
NCT02603107

Comparison of Rosuvastatin With Atorvastatin in Chronic Periodontitis

Phase 2
Completed
Conditions
Chronic Periodontitis
Interventions
Drug: SRP with RSV gel LDD
Drug: SRP with ATV gel LDD
Drug: SRP with placebo gel LDD
First Posted Date
2015-11-09
Last Posted Date
2015-11-13
Lead Sponsor
Government Dental College and Research Institute, Bangalore
Target Recruit Count
45
Registration Number
NCT02600520

Comparison of Autologous PRF, 1% Alendronate and 1.2% Atorvastatin Gel in Chronic Periodontitis Treatment

Phase 2
Completed
Conditions
Chronic Periodontitis
Interventions
Procedure: Open flap debridement (OFD)
Drug: OFD with ATV
Biological: OFD with PRF
Drug: OFD with ALN
First Posted Date
2015-08-05
Last Posted Date
2015-08-05
Lead Sponsor
Government Dental College and Research Institute, Bangalore
Target Recruit Count
120
Registration Number
NCT02516111
© Copyright 2025. All Rights Reserved by MedPath